Pharmacological inhibitors of MAPK pathways

Trends in Pharmacological Sciences

Volumn 23, Issue 1, 2002, Pages 40-45

  English, Jessie M ^a   Cobb, Melanie H ^b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 5 (2 AMINO 4 PYRIMIDINYL) 4 (4 FLUOROPHENYL) 1 (4 PIPERIDINYL)IMIDAZOLE; 5 (4 PYRIDINYL) 4 (4 FLUOROPHENYL) 1 (4 PIPERIDINYL)IMIDAZOLE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; CEP 1347; CYTOKINE; IMIDAZOLE DERIVATIVE; L 783277; LLZ 16402; MITOGEN ACTIVATED PROTEIN KINASE 1; PROTEIN; PROTEIN KINASE; RO 092210; SB 216995; SB 218655; SYNAPTOPHYSIN; UNCLASSIFIED DRUG;

CANCER; CYTOKINE PRODUCTION; DRUG POTENCY; DRUG SPECIFICITY; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; INFLAMMATORY DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; STRESS;

ANIMALS; DRUG DESIGN; DRUGS, INVESTIGATIONAL; ENZYME INHIBITORS; HUMANS; MAP KINASE KINASE 1; MAP KINASE KINASE 2; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MITOGEN-ACTIVATED PROTEIN KINASES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-RAF; SUBSTRATE SPECIFICITY;

EID: 0036165251     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-6147(00)01865-4     Document Type: Review

References (55)

1. Mitogen-activated protein (MAP) kinase pathways: Regulation and physiological functions
2. Signal transduction through MAP kinase cascades
3. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis
4. A synthetic inhibitor of the mitogen-activated protein kinase cascade
5. Identification of a novel inhibitor of mitogen-activated protein kinase kinase
6. Initial sequencing of the human genome
7. The sequence of the human genome
8. New inhibitors of p38 kinase
9. Inhibitors of p38 MAP kinase: Therapeutic intervention in cytokine-mediated diseases
10. p38 mitogen-activated protein kinase inhibitors - Mechanisms and therapeutic potentials
11. Inhibition of p38 MAP kinase as a therapeutic strategy
12. SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistence
13. SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lung
14. RWJ 67657, a potent, orally active inhibitor of p38 mitogen-activated protein kinase
15. RPR203494 a pyrimidine analogue of the p38 inhibitor RPR200765A with an improved in vitro potency
16. SAR of 4-hydroxy-piperidine and hydroxyalkyl substituted heterocycles as novel p38 map kinase inhibitors
17. How MAP kinases are regulated
18. Active and inactive protein kinases: Structural basis for regulation
19. Structural analysis of receptor tyrosine kinases
20. Crystal structure of p38 mitogen-activated protein kinase
21. The structure of mitogen-activated protein kinase p38 at 2.1-Å resolution
22. Structural basis of inhibitor selectivity in MAP kinases
23. The SHAPES strategy: An NMR-based approach for lead generation in drug discovery
24. Consensus scoring: A method for obtaining improved hit rates from docking databases of three-dimensional structures into proteins
25. Acquisition of sensitivity of stress-activated protein kinases to the p38 inhibitor, SB 203580, by alteration of one or more amino acids within the ATP binding pocket
26. Conversion of SB 203580-insensitive MAP kinase family members to drug-sensitive forms by a single amino-acid substitution
27. A single amino acid substitution makes ERK2 susceptible to pyridinyl imidazole inhibitors of p38 MAP kinase
28. Molecular basis for p38 protein kinase inhibitor specificity
29. A highly specific inhibitor of human p38 MAP kinase binds in the ATP pocket
30. The structural basis for the specificity of pyridinylimidazole inhibitors of p38 MAP kinase
31. Effect of SB 203580 on the activity of c-Raf in vitro and in vivo
32. Specificity and mechanism of action of some commonly used protein kinase inhibitors
33. Design and synthesis of potent, selective, and orally bioavailable tetrasubstituted imidazole inhibitors of p38 mitogen-activated protein kinase
34. The activation state of p38 mitogen-activated protein kinase determines the efficiency of ATP competition for pyridinylimidazole inhibitor binding
35. Kinetic mechanism and ATP-binding site reactivity of p38γ MAP kinase
36. PD098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo
37. Constitutive activation of the 41-/43-kDa mitogen activated protein kinase signaling pathway in human tumors
38. Development of anticancer drugs targeting the MAP kinase pathway
39. Pharmacological inhibitors of MKK1 and MKK2
40. Activation of the protein kinase ERK5/BMK1 by receptor tyrosine kinases. Identification and characterization of a signaling pathway to the nucleus
41. Differential MAPK pathways utilized for HGF and EGF-dependent renal epithelial morphogenesis
42. Effects of MAP kinase cascade inhibitors on the MKK5/ERK5 pathway
43. Direct inhibition of cyclooxygenase-1 and -2 by the kinase inhibitors SB 203580 and PD 98059. SB 203580 also inhibits thromboxane synthase
44. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo
45. Determinants of sensitivity to MAP kinase pathway intervention by MEK inhibition
46. Synthesis and structure-activity relationships of 3-cyano-4- (phenoxyanilino)quinolines as MEK (MAPKK) inhibitors
47. Ro 09-2210 exhibits potent anti-proliferative effects on activated T cells by selectively blocking MKK activity
48. Resorcylic acid lactones: Naturally occurring potent and selective inhibitors of MEK
49. A radicicol-related macrocyclic nonaketide compound, antibiotic LL-Z1640-2, inhibits the JNK/p38 pathways in signal-specific manner
50. c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis
51. Motoneuron apoptosis is blocked by CEP-1347 (KT 7515), a novel inhibitor of the JNK signaling pathway
52. CEP-1347 (KT7515), a semisynthetic inhibitor of the mixed lineage kinase family
53. The discovery of potent cRaf1 kinase inhibitors
54. Identification of potent, selective kinase inhibitors of Raf
55. Phase 1 and pharmacokinetic study of the Raf kinase inhibitor Bay 43-9006 in patients with locally advanced or metastatic cancer